nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—BTK—Mitoxantrone—prostate cancer	0.0915	0.491	CbGbCtD
Bosutinib—PRKCQ—prostate cancer	0.0812	0.17	CbGaD
Bosutinib—EPHB2—prostate cancer	0.0812	0.17	CbGaD
Bosutinib—IRAK4—prostate cancer	0.0723	0.152	CbGaD
Bosutinib—MAP3K7—prostate cancer	0.0548	0.115	CbGaD
Bosutinib—MAP2K1—prostate cancer	0.0466	0.0978	CbGaD
Bosutinib—CHEK2—prostate cancer	0.0373	0.0782	CbGaD
Bosutinib—ERBB3—prostate cancer	0.0332	0.0697	CbGaD
Bosutinib—PDGFRB—prostate cancer	0.0275	0.0576	CbGaD
Bosutinib—EGFR—Docetaxel—prostate cancer	0.0241	0.129	CbGbCtD
Bosutinib—SRC—prostate cancer	0.0222	0.0465	CbGaD
Bosutinib—EGFR—prostate cancer	0.0149	0.0312	CbGaD
Bosutinib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00796	0.0427	CbGbCtD
Bosutinib—ABCB1—Estramustine—prostate cancer	0.00649	0.0348	CbGbCtD
Bosutinib—CYP3A4—prostate cancer	0.00544	0.0114	CbGaD
Bosutinib—ABCB1—Cabazitaxel—prostate cancer	0.00428	0.0229	CbGbCtD
Bosutinib—CYP3A4—Bicalutamide—prostate cancer	0.00418	0.0224	CbGbCtD
Bosutinib—ABCB1—Estrone—prostate cancer	0.00418	0.0224	CbGbCtD
Bosutinib—CYP3A4—Estramustine—prostate cancer	0.00389	0.0208	CbGbCtD
Bosutinib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00372	0.02	CbGbCtD
Bosutinib—CYP3A4—Flutamide—prostate cancer	0.00346	0.0186	CbGbCtD
Bosutinib—CYP3A4—Abiraterone—prostate cancer	0.00346	0.0186	CbGbCtD
Bosutinib—ABCB1—Conjugated Estrogens—prostate cancer	0.00273	0.0147	CbGbCtD
Bosutinib—CYP3A4—Cabazitaxel—prostate cancer	0.00256	0.0137	CbGbCtD
Bosutinib—CYP3A4—Estrone—prostate cancer	0.0025	0.0134	CbGbCtD
Bosutinib—ABCB1—Mitoxantrone—prostate cancer	0.00249	0.0133	CbGbCtD
Bosutinib—ABCB1—Estradiol—prostate cancer	0.0024	0.0129	CbGbCtD
Bosutinib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00223	0.012	CbGbCtD
Bosutinib—ABCB1—Prednisone—prostate cancer	0.00206	0.0111	CbGbCtD
Bosutinib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00164	0.00878	CbGbCtD
Bosutinib—ABCB1—Etoposide—prostate cancer	0.00157	0.00841	CbGbCtD
Bosutinib—CYP3A4—Mitoxantrone—prostate cancer	0.00149	0.00799	CbGbCtD
Bosutinib—CYP3A4—Estradiol—prostate cancer	0.00144	0.00771	CbGbCtD
Bosutinib—ABCB1—Docetaxel—prostate cancer	0.00143	0.00769	CbGbCtD
Bosutinib—CYP3A4—Prednisone—prostate cancer	0.00124	0.00663	CbGbCtD
Bosutinib—ABCB1—Doxorubicin—prostate cancer	0.00107	0.00573	CbGbCtD
Bosutinib—CYP3A4—Etoposide—prostate cancer	0.000939	0.00504	CbGbCtD
Bosutinib—CYP3A4—Docetaxel—prostate cancer	0.000859	0.00461	CbGbCtD
Bosutinib—CYP3A4—Doxorubicin—prostate cancer	0.00064	0.00343	CbGbCtD
Bosutinib—Vandetanib—BMPR1B—prostate cancer	0.000596	0.154	CrCbGaD
Bosutinib—Vandetanib—IRAK4—prostate cancer	0.000596	0.154	CrCbGaD
Bosutinib—Gefitinib—IRAK4—prostate cancer	0.000566	0.146	CrCbGaD
Bosutinib—WEE1—Paclitaxel—Cabazitaxel—prostate cancer	0.000428	0.148	CbGdCrCtD
Bosutinib—CDK2—Paclitaxel—Cabazitaxel—prostate cancer	0.000349	0.121	CbGdCrCtD
Bosutinib—Gefitinib—CHEK2—prostate cancer	0.000292	0.0754	CrCbGaD
Bosutinib—Vandetanib—ERBB3—prostate cancer	0.000273	0.0707	CrCbGaD
Bosutinib—Gefitinib—ERBB3—prostate cancer	0.00026	0.0672	CrCbGaD
Bosutinib—Vandetanib—PDGFRB—prostate cancer	0.000226	0.0585	CrCbGaD
Bosutinib—Vandetanib—SRC—prostate cancer	0.000182	0.0472	CrCbGaD
Bosutinib—WEE1—Paclitaxel—Docetaxel—prostate cancer	0.000178	0.0615	CbGdCrCtD
Bosutinib—MAP4K1—bone marrow—prostate cancer	0.000173	0.00205	CbGeAlD
Bosutinib—RPS6KB1—epithelium—prostate cancer	0.000173	0.00205	CbGeAlD
Bosutinib—BTK—bone marrow—prostate cancer	0.000172	0.00204	CbGeAlD
Bosutinib—IRAK4—urethra—prostate cancer	0.000172	0.00204	CbGeAlD
Bosutinib—SIK1—urethra—prostate cancer	0.000172	0.00204	CbGeAlD
Bosutinib—STK25—testis—prostate cancer	0.000172	0.00204	CbGeAlD
Bosutinib—ERBB3—renal system—prostate cancer	0.000172	0.00204	CbGeAlD
Bosutinib—MAP2K2—renal system—prostate cancer	0.000172	0.00203	CbGeAlD
Bosutinib—Vandetanib—KDR—prostate cancer	0.000171	0.0443	CrCbGaD
Bosutinib—EPHA3—testis—prostate cancer	0.000171	0.00202	CbGeAlD
Bosutinib—EPHA4—urethra—prostate cancer	0.000171	0.00202	CbGeAlD
Bosutinib—CSF1R—prostate gland—prostate cancer	0.00017	0.00201	CbGeAlD
Bosutinib—MAP2K2—urethra—prostate cancer	0.000169	0.002	CbGeAlD
Bosutinib—ULK3—urethra—prostate cancer	0.000169	0.002	CbGeAlD
Bosutinib—MAP4K2—bone marrow—prostate cancer	0.000168	0.00199	CbGeAlD
Bosutinib—PLK2—testis—prostate cancer	0.000167	0.00198	CbGeAlD
Bosutinib—PTK2—renal system—prostate cancer	0.000167	0.00198	CbGeAlD
Bosutinib—TBK1—renal system—prostate cancer	0.000167	0.00198	CbGeAlD
Bosutinib—YES1—seminal vesicle—prostate cancer	0.000166	0.00197	CbGeAlD
Bosutinib—SIK3—testis—prostate cancer	0.000166	0.00197	CbGeAlD
Bosutinib—MAP3K7—urethra—prostate cancer	0.000166	0.00196	CbGeAlD
Bosutinib—CYP3A4—urine—prostate cancer	0.000164	0.00195	CbGeAlD
Bosutinib—TAOK3—seminal vesicle—prostate cancer	0.000164	0.00195	CbGeAlD
Bosutinib—PTK2—urethra—prostate cancer	0.000164	0.00194	CbGeAlD
Bosutinib—TBK1—urethra—prostate cancer	0.000164	0.00194	CbGeAlD
Bosutinib—EPHB4—epithelium—prostate cancer	0.000164	0.00194	CbGeAlD
Bosutinib—TLK1—lymph node—prostate cancer	0.000163	0.00194	CbGeAlD
Bosutinib—PRKCQ—lymph node—prostate cancer	0.000161	0.00191	CbGeAlD
Bosutinib—EPHA2—epithelium—prostate cancer	0.000161	0.0019	CbGeAlD
Bosutinib—RPS6KB1—renal system—prostate cancer	0.00016	0.0019	CbGeAlD
Bosutinib—STK4—testis—prostate cancer	0.00016	0.0019	CbGeAlD
Bosutinib—CAMK1D—testis—prostate cancer	0.000158	0.00187	CbGeAlD
Bosutinib—RPS6KB1—urethra—prostate cancer	0.000158	0.00187	CbGeAlD
Bosutinib—FGR—urethra—prostate cancer	0.000157	0.00186	CbGeAlD
Bosutinib—LCK—urethra—prostate cancer	0.000157	0.00186	CbGeAlD
Bosutinib—STK24—testis—prostate cancer	0.000156	0.00185	CbGeAlD
Bosutinib—AXL—urethra—prostate cancer	0.000156	0.00185	CbGeAlD
Bosutinib—MERTK—bone marrow—prostate cancer	0.000155	0.00184	CbGeAlD
Bosutinib—CHEK2—Docetaxel—Cabazitaxel—prostate cancer	0.000155	0.0536	CbGdCrCtD
Bosutinib—MAP4K4—bone marrow—prostate cancer	0.000153	0.00181	CbGeAlD
Bosutinib—EPHB4—renal system—prostate cancer	0.000152	0.0018	CbGeAlD
Bosutinib—BCR—bone marrow—prostate cancer	0.000151	0.00179	CbGeAlD
Bosutinib—NUAK2—bone marrow—prostate cancer	0.000151	0.00179	CbGeAlD
Bosutinib—FER—testis—prostate cancer	0.000151	0.00179	CbGeAlD
Bosutinib—ALK—testis—prostate cancer	0.000151	0.00179	CbGeAlD
Bosutinib—TYRO3—testis—prostate cancer	0.000151	0.00179	CbGeAlD
Bosutinib—DSTYK—lymph node—prostate cancer	0.000151	0.00179	CbGeAlD
Bosutinib—BMX—lymph node—prostate cancer	0.000151	0.00179	CbGeAlD
Bosutinib—CLK3—lymph node—prostate cancer	0.000151	0.00179	CbGeAlD
Bosutinib—PDGFRB—prostate gland—prostate cancer	0.000151	0.00179	CbGeAlD
Bosutinib—SLK—urethra—prostate cancer	0.00015	0.00178	CbGeAlD
Bosutinib—BLK—lymph node—prostate cancer	0.000149	0.00177	CbGeAlD
Bosutinib—EPHB4—urethra—prostate cancer	0.000149	0.00177	CbGeAlD
Bosutinib—FYN—renal system—prostate cancer	0.000149	0.00176	CbGeAlD
Bosutinib—MAP3K19—testis—prostate cancer	0.000148	0.00175	CbGeAlD
Bosutinib—MAP4K1—testis—prostate cancer	0.000148	0.00175	CbGeAlD
Bosutinib—CASK—lymph node—prostate cancer	0.000148	0.00175	CbGeAlD
Bosutinib—PHKG1—lymph node—prostate cancer	0.000148	0.00175	CbGeAlD
Bosutinib—BTK—testis—prostate cancer	0.000147	0.00175	CbGeAlD
Bosutinib—MAP2K5—seminal vesicle—prostate cancer	0.000147	0.00175	CbGeAlD
Bosutinib—MAP2K1—bone marrow—prostate cancer	0.000147	0.00175	CbGeAlD
Bosutinib—CSK—bone marrow—prostate cancer	0.000146	0.00173	CbGeAlD
Bosutinib—EPHA2—urethra—prostate cancer	0.000146	0.00173	CbGeAlD
Bosutinib—EIF2AK1—lymph node—prostate cancer	0.000146	0.00173	CbGeAlD
Bosutinib—FYN—urethra—prostate cancer	0.000146	0.00173	CbGeAlD
Bosutinib—CSNK1A1—bone marrow—prostate cancer	0.000145	0.00172	CbGeAlD
Bosutinib—Vandetanib—VEGFA—prostate cancer	0.000145	0.0376	CrCbGaD
Bosutinib—TNK2—testis—prostate cancer	0.000145	0.00172	CbGeAlD
Bosutinib—CDK2—Paclitaxel—Docetaxel—prostate cancer	0.000145	0.0501	CbGdCrCtD
Bosutinib—HCK—bone marrow—prostate cancer	0.000144	0.00171	CbGeAlD
Bosutinib—CLK1—bone marrow—prostate cancer	0.000144	0.00171	CbGeAlD
Bosutinib—CSF1R—seminal vesicle—prostate cancer	0.000144	0.0017	CbGeAlD
Bosutinib—MAP4K2—testis—prostate cancer	0.000143	0.0017	CbGeAlD
Bosutinib—TXK—lymph node—prostate cancer	0.000143	0.0017	CbGeAlD
Bosutinib—MAP4K5—urethra—prostate cancer	0.000143	0.00169	CbGeAlD
Bosutinib—MAP3K3—urethra—prostate cancer	0.000143	0.00169	CbGeAlD
Bosutinib—BMP2K—bone marrow—prostate cancer	0.000142	0.00168	CbGeAlD
Bosutinib—CAMK2G—bone marrow—prostate cancer	0.000142	0.00168	CbGeAlD
Bosutinib—FES—lymph node—prostate cancer	0.000142	0.00168	CbGeAlD
Bosutinib—VRK2—lymph node—prostate cancer	0.000142	0.00168	CbGeAlD
Bosutinib—ERBB4—testis—prostate cancer	0.000141	0.00167	CbGeAlD
Bosutinib—STK3—testis—prostate cancer	0.000141	0.00167	CbGeAlD
Bosutinib—LRRK2—bone marrow—prostate cancer	0.000141	0.00167	CbGeAlD
Bosutinib—ROCK1—testis—prostate cancer	0.000139	0.00165	CbGeAlD
Bosutinib—SRC—epithelium—prostate cancer	0.000139	0.00165	CbGeAlD
Bosutinib—TNIK—lymph node—prostate cancer	0.000139	0.00165	CbGeAlD
Bosutinib—SYK—lymph node—prostate cancer	0.000139	0.00165	CbGeAlD
Bosutinib—CDK2—lymph node—prostate cancer	0.000138	0.00163	CbGeAlD
Bosutinib—PTK2B—bone marrow—prostate cancer	0.000137	0.00162	CbGeAlD
Bosutinib—STK26—lymph node—prostate cancer	0.000136	0.00162	CbGeAlD
Bosutinib—BMPR2—testis—prostate cancer	0.000135	0.00161	CbGeAlD
Bosutinib—STK36—testis—prostate cancer	0.000134	0.00159	CbGeAlD
Bosutinib—EPHB3—testis—prostate cancer	0.000134	0.00159	CbGeAlD
Bosutinib—ABL1—prostate gland—prostate cancer	0.000134	0.00159	CbGeAlD
Bosutinib—YES1—renal system—prostate cancer	0.000134	0.00159	CbGeAlD
Bosutinib—STK10—renal system—prostate cancer	0.000133	0.00158	CbGeAlD
Bosutinib—MERTK—testis—prostate cancer	0.000133	0.00157	CbGeAlD
Bosutinib—SIK1—bone marrow—prostate cancer	0.000133	0.00157	CbGeAlD
Bosutinib—IRAK4—bone marrow—prostate cancer	0.000133	0.00157	CbGeAlD
Bosutinib—TAOK3—renal system—prostate cancer	0.000132	0.00157	CbGeAlD
Bosutinib—YES1—urethra—prostate cancer	0.000132	0.00156	CbGeAlD
Bosutinib—CHEK2—lymph node—prostate cancer	0.000132	0.00156	CbGeAlD
Bosutinib—WEE1—lymph node—prostate cancer	0.000131	0.00155	CbGeAlD
Bosutinib—DMPK—lymph node—prostate cancer	0.000131	0.00155	CbGeAlD
Bosutinib—MAP4K4—testis—prostate cancer	0.00013	0.00154	CbGeAlD
Bosutinib—TAOK3—urethra—prostate cancer	0.00013	0.00154	CbGeAlD
Bosutinib—MAP2K2—bone marrow—prostate cancer	0.00013	0.00154	CbGeAlD
Bosutinib—ULK3—bone marrow—prostate cancer	0.00013	0.00154	CbGeAlD
Bosutinib—NUAK2—testis—prostate cancer	0.000129	0.00153	CbGeAlD
Bosutinib—BCR—testis—prostate cancer	0.000129	0.00153	CbGeAlD
Bosutinib—SRC—renal system—prostate cancer	0.000129	0.00153	CbGeAlD
Bosutinib—MAP3K2—bone marrow—prostate cancer	0.000129	0.00153	CbGeAlD
Bosutinib—MAP3K12—testis—prostate cancer	0.000129	0.00152	CbGeAlD
Bosutinib—MAP3K7—bone marrow—prostate cancer	0.000128	0.00151	CbGeAlD
Bosutinib—PDGFRB—seminal vesicle—prostate cancer	0.000128	0.00151	CbGeAlD
Bosutinib—TBK1—bone marrow—prostate cancer	0.000126	0.00149	CbGeAlD
Bosutinib—MAP2K1—testis—prostate cancer	0.000126	0.00149	CbGeAlD
Bosutinib—STK35—testis—prostate cancer	0.000126	0.00149	CbGeAlD
Bosutinib—CSK—testis—prostate cancer	0.000125	0.00148	CbGeAlD
Bosutinib—STK25—lymph node—prostate cancer	0.000125	0.00148	CbGeAlD
Bosutinib—CSNK1A1—testis—prostate cancer	0.000124	0.00147	CbGeAlD
Bosutinib—EPHA3—lymph node—prostate cancer	0.000124	0.00147	CbGeAlD
Bosutinib—IRAK1—bone marrow—prostate cancer	0.000124	0.00146	CbGeAlD
Bosutinib—HCK—testis—prostate cancer	0.000124	0.00146	CbGeAlD
Bosutinib—CLK1—testis—prostate cancer	0.000124	0.00146	CbGeAlD
Bosutinib—ABL2—testis—prostate cancer	0.000123	0.00145	CbGeAlD
Bosutinib—Vandetanib—EGFR—prostate cancer	0.000123	0.0317	CrCbGaD
Bosutinib—MAP4K4—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	0.000121	0.042	CbGdCrCtD
Bosutinib—RPS6KB1—bone marrow—prostate cancer	0.000121	0.00144	CbGeAlD
Bosutinib—PLK2—lymph node—prostate cancer	0.000121	0.00144	CbGeAlD
Bosutinib—CAMK2G—testis—prostate cancer	0.000121	0.00144	CbGeAlD
Bosutinib—BMP2K—testis—prostate cancer	0.000121	0.00144	CbGeAlD
Bosutinib—LCK—bone marrow—prostate cancer	0.000121	0.00143	CbGeAlD
Bosutinib—FGR—bone marrow—prostate cancer	0.000121	0.00143	CbGeAlD
Bosutinib—SIK3—lymph node—prostate cancer	0.00012	0.00143	CbGeAlD
Bosutinib—LRRK2—testis—prostate cancer	0.00012	0.00142	CbGeAlD
Bosutinib—EGFR—testis—prostate cancer	0.00012	0.00142	CbGeAlD
Bosutinib—PTK2B—testis—prostate cancer	0.000117	0.00139	CbGeAlD
Bosutinib—MAP2K5—urethra—prostate cancer	0.000117	0.00138	CbGeAlD
Bosutinib—Gefitinib—EGFR—prostate cancer	0.000117	0.0301	CrCbGaD
Bosutinib—STK4—lymph node—prostate cancer	0.000116	0.00137	CbGeAlD
Bosutinib—SLK—bone marrow—prostate cancer	0.000116	0.00137	CbGeAlD
Bosutinib—CSNK1E—testis—prostate cancer	0.000115	0.00136	CbGeAlD
Bosutinib—EPHB4—bone marrow—prostate cancer	0.000115	0.00136	CbGeAlD
Bosutinib—CAMK1D—lymph node—prostate cancer	0.000115	0.00136	CbGeAlD
Bosutinib—CSF1R—urethra—prostate cancer	0.000114	0.00135	CbGeAlD
Bosutinib—ABL1—seminal vesicle—prostate cancer	0.000114	0.00135	CbGeAlD
Bosutinib—SIK1—testis—prostate cancer	0.000113	0.00134	CbGeAlD
Bosutinib—IRAK4—testis—prostate cancer	0.000113	0.00134	CbGeAlD
Bosutinib—STK24—lymph node—prostate cancer	0.000113	0.00134	CbGeAlD
Bosutinib—FYN—bone marrow—prostate cancer	0.000112	0.00133	CbGeAlD
Bosutinib—EPHA4—testis—prostate cancer	0.000112	0.00133	CbGeAlD
Bosutinib—ERBB3—testis—prostate cancer	0.000111	0.00132	CbGeAlD
Bosutinib—ULK3—testis—prostate cancer	0.000111	0.00131	CbGeAlD
Bosutinib—MAP2K2—testis—prostate cancer	0.000111	0.00131	CbGeAlD
Bosutinib—PDGFRB—epithelium—prostate cancer	0.000111	0.00131	CbGeAlD
Bosutinib—MAP3K2—testis—prostate cancer	0.00011	0.0013	CbGeAlD
Bosutinib—MAP4K5—bone marrow—prostate cancer	0.00011	0.0013	CbGeAlD
Bosutinib—MAP3K3—bone marrow—prostate cancer	0.00011	0.0013	CbGeAlD
Bosutinib—ALK—lymph node—prostate cancer	0.00011	0.0013	CbGeAlD
Bosutinib—FER—lymph node—prostate cancer	0.00011	0.0013	CbGeAlD
Bosutinib—MAP3K7—testis—prostate cancer	0.000109	0.00129	CbGeAlD
Bosutinib—STK25—Estriol—Estramustine—prostate cancer	0.000109	0.0377	CbGdCrCtD
Bosutinib—TBK1—testis—prostate cancer	0.000108	0.00128	CbGeAlD
Bosutinib—PTK2—testis—prostate cancer	0.000108	0.00128	CbGeAlD
Bosutinib—MAP4K1—lymph node—prostate cancer	0.000107	0.00127	CbGeAlD
Bosutinib—CHEK2—Paclitaxel—Cabazitaxel—prostate cancer	0.000107	0.037	CbGdCrCtD
Bosutinib—BTK—lymph node—prostate cancer	0.000107	0.00127	CbGeAlD
Bosutinib—IRAK1—testis—prostate cancer	0.000106	0.00125	CbGeAlD
Bosutinib—TNK2—lymph node—prostate cancer	0.000105	0.00125	CbGeAlD
Bosutinib—MAP4K2—lymph node—prostate cancer	0.000104	0.00123	CbGeAlD
Bosutinib—RPS6KB1—testis—prostate cancer	0.000104	0.00123	CbGeAlD
Bosutinib—FGR—testis—prostate cancer	0.000103	0.00122	CbGeAlD
Bosutinib—LCK—testis—prostate cancer	0.000103	0.00122	CbGeAlD
Bosutinib—PDGFRB—renal system—prostate cancer	0.000103	0.00122	CbGeAlD
Bosutinib—AXL—testis—prostate cancer	0.000103	0.00122	CbGeAlD
Bosutinib—STK3—lymph node—prostate cancer	0.000102	0.00121	CbGeAlD
Bosutinib—STK24—Teniposide—Etoposide—prostate cancer	0.000102	0.0352	CbGdCrCtD
Bosutinib—YES1—bone marrow—prostate cancer	0.000101	0.0012	CbGeAlD
Bosutinib—PDGFRB—urethra—prostate cancer	0.000101	0.0012	CbGeAlD
Bosutinib—STK10—bone marrow—prostate cancer	0.000101	0.00119	CbGeAlD
Bosutinib—TAOK3—bone marrow—prostate cancer	0.0001	0.00119	CbGeAlD
Bosutinib—SLK—testis—prostate cancer	9.88e-05	0.00117	CbGeAlD
Bosutinib—Gefitinib—CYP3A5—prostate cancer	9.83e-05	0.0254	CrCbGaD
Bosutinib—BMPR2—lymph node—prostate cancer	9.82e-05	0.00116	CbGeAlD
Bosutinib—EPHB4—testis—prostate cancer	9.81e-05	0.00116	CbGeAlD
Bosutinib—STK36—lymph node—prostate cancer	9.74e-05	0.00115	CbGeAlD
Bosutinib—EPHB3—lymph node—prostate cancer	9.74e-05	0.00115	CbGeAlD
Bosutinib—MERTK—lymph node—prostate cancer	9.63e-05	0.00114	CbGeAlD
Bosutinib—EPHA2—testis—prostate cancer	9.62e-05	0.00114	CbGeAlD
Bosutinib—FYN—testis—prostate cancer	9.61e-05	0.00114	CbGeAlD
Bosutinib—MAP4K4—lymph node—prostate cancer	9.45e-05	0.00112	CbGeAlD
Bosutinib—MAP4K5—testis—prostate cancer	9.39e-05	0.00111	CbGeAlD
Bosutinib—MAP3K3—testis—prostate cancer	9.39e-05	0.00111	CbGeAlD
Bosutinib—NUAK2—lymph node—prostate cancer	9.38e-05	0.00111	CbGeAlD
Bosutinib—BCR—lymph node—prostate cancer	9.38e-05	0.00111	CbGeAlD
Bosutinib—MAP3K12—lymph node—prostate cancer	9.32e-05	0.0011	CbGeAlD
Bosutinib—ABL1—renal system—prostate cancer	9.16e-05	0.00109	CbGeAlD
Bosutinib—STK35—lymph node—prostate cancer	9.13e-05	0.00108	CbGeAlD
Bosutinib—MAP2K1—lymph node—prostate cancer	9.13e-05	0.00108	CbGeAlD
Bosutinib—CSK—lymph node—prostate cancer	9.07e-05	0.00107	CbGeAlD
Bosutinib—CSNK1A1—lymph node—prostate cancer	9.01e-05	0.00107	CbGeAlD
Bosutinib—ABL1—urethra—prostate cancer	9e-05	0.00107	CbGeAlD
Bosutinib—HCK—lymph node—prostate cancer	8.95e-05	0.00106	CbGeAlD
Bosutinib—CLK1—lymph node—prostate cancer	8.95e-05	0.00106	CbGeAlD
Bosutinib—ABL2—lymph node—prostate cancer	8.9e-05	0.00105	CbGeAlD
Bosutinib—CAMK2G—lymph node—prostate cancer	8.79e-05	0.00104	CbGeAlD
Bosutinib—BMP2K—lymph node—prostate cancer	8.79e-05	0.00104	CbGeAlD
Bosutinib—CSF1R—bone marrow—prostate cancer	8.76e-05	0.00104	CbGeAlD
Bosutinib—LRRK2—lymph node—prostate cancer	8.71e-05	0.00103	CbGeAlD
Bosutinib—EGFR—lymph node—prostate cancer	8.68e-05	0.00103	CbGeAlD
Bosutinib—YES1—testis—prostate cancer	8.67e-05	0.00103	CbGeAlD
Bosutinib—STK25—Estriol—Estrone—prostate cancer	8.64e-05	0.0299	CbGdCrCtD
Bosutinib—STK10—testis—prostate cancer	8.59e-05	0.00102	CbGeAlD
Bosutinib—TAOK3—testis—prostate cancer	8.56e-05	0.00101	CbGeAlD
Bosutinib—PTK2B—lymph node—prostate cancer	8.49e-05	0.00101	CbGeAlD
Bosutinib—CSNK1E—lymph node—prostate cancer	8.35e-05	0.000989	CbGeAlD
Bosutinib—SRC—testis—prostate cancer	8.34e-05	0.000988	CbGeAlD
Bosutinib—SIK1—lymph node—prostate cancer	8.22e-05	0.000974	CbGeAlD
Bosutinib—IRAK4—lymph node—prostate cancer	8.22e-05	0.000974	CbGeAlD
Bosutinib—EPHA4—lymph node—prostate cancer	8.14e-05	0.000964	CbGeAlD
Bosutinib—ERBB3—lymph node—prostate cancer	8.06e-05	0.000955	CbGeAlD
Bosutinib—MAP2K2—lymph node—prostate cancer	8.04e-05	0.000952	CbGeAlD
Bosutinib—ULK3—lymph node—prostate cancer	8.04e-05	0.000952	CbGeAlD
Bosutinib—MAP3K2—lymph node—prostate cancer	7.98e-05	0.000945	CbGeAlD
Bosutinib—MAP3K7—lymph node—prostate cancer	7.9e-05	0.000937	CbGeAlD
Bosutinib—PTK2—lymph node—prostate cancer	7.81e-05	0.000926	CbGeAlD
Bosutinib—TBK1—lymph node—prostate cancer	7.81e-05	0.000926	CbGeAlD
Bosutinib—PDGFRB—bone marrow—prostate cancer	7.77e-05	0.000921	CbGeAlD
Bosutinib—MAP2K5—testis—prostate cancer	7.67e-05	0.000909	CbGeAlD
Bosutinib—IRAK1—lymph node—prostate cancer	7.66e-05	0.000908	CbGeAlD
Bosutinib—STK25—Estriol—Conjugated Estrogens—prostate cancer	7.6e-05	0.0263	CbGdCrCtD
Bosutinib—RPS6KB1—lymph node—prostate cancer	7.52e-05	0.000891	CbGeAlD
Bosutinib—CSF1R—testis—prostate cancer	7.49e-05	0.000887	CbGeAlD
Bosutinib—LCK—lymph node—prostate cancer	7.47e-05	0.000885	CbGeAlD
Bosutinib—FGR—lymph node—prostate cancer	7.47e-05	0.000885	CbGeAlD
Bosutinib—AXL—lymph node—prostate cancer	7.44e-05	0.000882	CbGeAlD
Bosutinib—SLK—lymph node—prostate cancer	7.16e-05	0.000849	CbGeAlD
Bosutinib—EPHB4—lymph node—prostate cancer	7.11e-05	0.000843	CbGeAlD
Bosutinib—EPHA2—lymph node—prostate cancer	6.98e-05	0.000827	CbGeAlD
Bosutinib—FYN—lymph node—prostate cancer	6.96e-05	0.000825	CbGeAlD
Bosutinib—ABL1—bone marrow—prostate cancer	6.93e-05	0.000821	CbGeAlD
Bosutinib—MAP4K5—lymph node—prostate cancer	6.81e-05	0.000806	CbGeAlD
Bosutinib—MAP3K3—lymph node—prostate cancer	6.81e-05	0.000806	CbGeAlD
Bosutinib—Gefitinib—CYP2C19—prostate cancer	6.69e-05	0.0173	CrCbGaD
Bosutinib—Gefitinib—CYP1A1—prostate cancer	6.67e-05	0.0172	CrCbGaD
Bosutinib—PDGFRB—testis—prostate cancer	6.64e-05	0.000787	CbGeAlD
Bosutinib—PKMYT1—Fulvestrant—Estradiol—prostate cancer	6.63e-05	0.023	CbGdCrCtD
Bosutinib—CASK—Teniposide—Etoposide—prostate cancer	6.55e-05	0.0227	CbGdCrCtD
Bosutinib—STK25—Estriol—Estradiol—prostate cancer	6.55e-05	0.0227	CbGdCrCtD
Bosutinib—STK25—Estriol—Ethinyl Estradiol—prostate cancer	6.39e-05	0.0221	CbGdCrCtD
Bosutinib—PLK2—Levonorgestrel—Ethinyl Estradiol—prostate cancer	6.29e-05	0.0218	CbGdCrCtD
Bosutinib—YES1—lymph node—prostate cancer	6.29e-05	0.000745	CbGeAlD
Bosutinib—STK10—lymph node—prostate cancer	6.23e-05	0.000738	CbGeAlD
Bosutinib—TAOK3—lymph node—prostate cancer	6.21e-05	0.000735	CbGeAlD
Bosutinib—SRC—lymph node—prostate cancer	6.05e-05	0.000716	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Epirubicin—prostate cancer	5.95e-05	0.0206	CbGdCrCtD
Bosutinib—ABL1—testis—prostate cancer	5.92e-05	0.000701	CbGeAlD
Bosutinib—MAP2K5—lymph node—prostate cancer	5.56e-05	0.000659	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—prostate cancer	5.5e-05	0.0191	CbGdCrCtD
Bosutinib—CSF1R—lymph node—prostate cancer	5.43e-05	0.000643	CbGeAlD
Bosutinib—PDGFRB—lymph node—prostate cancer	4.81e-05	0.00057	CbGeAlD
Bosutinib—Vandetanib—CYP3A4—prostate cancer	4.48e-05	0.0116	CrCbGaD
Bosutinib—CHEK2—Paclitaxel—Docetaxel—prostate cancer	4.44e-05	0.0154	CbGdCrCtD
Bosutinib—ABL1—lymph node—prostate cancer	4.29e-05	0.000508	CbGeAlD
Bosutinib—Gefitinib—CYP3A4—prostate cancer	4.26e-05	0.011	CrCbGaD
Bosutinib—ERBB3—Podofilox—Etoposide—prostate cancer	4.22e-05	0.0146	CbGdCrCtD
Bosutinib—ABCB1—prostate gland—prostate cancer	4.18e-05	0.000495	CbGeAlD
Bosutinib—CYP3A4—renal system—prostate cancer	4.02e-05	0.000477	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—prostate cancer	4.01e-05	0.000398	CcSEcCtD
Bosutinib—Asthenia—Estradiol—prostate cancer	3.98e-05	0.000396	CcSEcCtD
Bosutinib—Neutropenia—Epirubicin—prostate cancer	3.97e-05	0.000394	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Epirubicin—prostate cancer	3.94e-05	0.000392	CcSEcCtD
Bosutinib—Ill-defined disorder—Capecitabine—prostate cancer	3.94e-05	0.000391	CcSEcCtD
Bosutinib—Pruritus—Estradiol—prostate cancer	3.93e-05	0.000391	CcSEcCtD
Bosutinib—Influenza—Doxorubicin—prostate cancer	3.93e-05	0.00039	CcSEcCtD
Bosutinib—Leukopenia—Docetaxel—prostate cancer	3.92e-05	0.00039	CcSEcCtD
Bosutinib—Anaemia—Capecitabine—prostate cancer	3.92e-05	0.00039	CcSEcCtD
Bosutinib—Immune system disorder—Prednisone—prostate cancer	3.92e-05	0.00039	CcSEcCtD
Bosutinib—Dyspnoea—Etoposide—prostate cancer	3.84e-05	0.000381	CcSEcCtD
Bosutinib—Malaise—Capecitabine—prostate cancer	3.83e-05	0.00038	CcSEcCtD
Bosutinib—Cough—Docetaxel—prostate cancer	3.82e-05	0.00038	CcSEcCtD
Bosutinib—Pneumonia—Epirubicin—prostate cancer	3.8e-05	0.000378	CcSEcCtD
Bosutinib—Diarrhoea—Estradiol—prostate cancer	3.8e-05	0.000378	CcSEcCtD
Bosutinib—Leukopenia—Capecitabine—prostate cancer	3.8e-05	0.000378	CcSEcCtD
Bosutinib—Infestation NOS—Epirubicin—prostate cancer	3.78e-05	0.000376	CcSEcCtD
Bosutinib—Infestation—Epirubicin—prostate cancer	3.78e-05	0.000376	CcSEcCtD
Bosutinib—Malnutrition—Prednisone—prostate cancer	3.78e-05	0.000376	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—prostate cancer	3.77e-05	0.000375	CcSEcCtD
Bosutinib—Decreased appetite—Etoposide—prostate cancer	3.74e-05	0.000372	CcSEcCtD
Bosutinib—Myalgia—Docetaxel—prostate cancer	3.73e-05	0.000371	CcSEcCtD
Bosutinib—Arthralgia—Docetaxel—prostate cancer	3.73e-05	0.000371	CcSEcCtD
Bosutinib—Chest pain—Docetaxel—prostate cancer	3.73e-05	0.000371	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—prostate cancer	3.73e-05	0.000371	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—prostate cancer	3.72e-05	0.00037	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Etoposide—prostate cancer	3.72e-05	0.000369	CcSEcCtD
Bosutinib—Asthenia—Mitoxantrone—prostate cancer	3.71e-05	0.000369	CcSEcCtD
Bosutinib—Fatigue—Etoposide—prostate cancer	3.71e-05	0.000369	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	3.71e-05	0.000368	CcSEcCtD
Bosutinib—Cough—Capecitabine—prostate cancer	3.7e-05	0.000368	CcSEcCtD
Bosutinib—Pain—Etoposide—prostate cancer	3.68e-05	0.000366	CcSEcCtD
Bosutinib—Dizziness—Estradiol—prostate cancer	3.67e-05	0.000365	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—prostate cancer	3.67e-05	0.000365	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—prostate cancer	3.65e-05	0.000363	CcSEcCtD
Bosutinib—Myalgia—Capecitabine—prostate cancer	3.61e-05	0.000359	CcSEcCtD
Bosutinib—Chest pain—Capecitabine—prostate cancer	3.61e-05	0.000359	CcSEcCtD
Bosutinib—Arthralgia—Capecitabine—prostate cancer	3.61e-05	0.000359	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	3.59e-05	0.000357	CcSEcCtD
Bosutinib—Hepatobiliary disease—Epirubicin—prostate cancer	3.58e-05	0.000356	CcSEcCtD
Bosutinib—Oedema—Docetaxel—prostate cancer	3.58e-05	0.000356	CcSEcCtD
Bosutinib—Anaphylactic shock—Docetaxel—prostate cancer	3.58e-05	0.000356	CcSEcCtD
Bosutinib—Discomfort—Capecitabine—prostate cancer	3.57e-05	0.000355	CcSEcCtD
Bosutinib—Infection—Docetaxel—prostate cancer	3.55e-05	0.000353	CcSEcCtD
Bosutinib—Feeling abnormal—Etoposide—prostate cancer	3.55e-05	0.000353	CcSEcCtD
Bosutinib—Diarrhoea—Mitoxantrone—prostate cancer	3.54e-05	0.000352	CcSEcCtD
Bosutinib—ABCB1—seminal vesicle—prostate cancer	3.53e-05	0.000419	CbGeAlD
Bosutinib—Vomiting—Estradiol—prostate cancer	3.53e-05	0.000351	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—prostate cancer	3.53e-05	0.000351	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—prostate cancer	3.52e-05	0.00035	CcSEcCtD
Bosutinib—Gastrointestinal pain—Etoposide—prostate cancer	3.52e-05	0.00035	CcSEcCtD
Bosutinib—Nervous system disorder—Docetaxel—prostate cancer	3.51e-05	0.000349	CcSEcCtD
Bosutinib—Ill-defined disorder—Prednisone—prostate cancer	3.51e-05	0.000349	CcSEcCtD
Bosutinib—Thrombocytopenia—Docetaxel—prostate cancer	3.5e-05	0.000348	CcSEcCtD
Bosutinib—Rash—Estradiol—prostate cancer	3.5e-05	0.000348	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—prostate cancer	3.5e-05	0.000348	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—prostate cancer	3.5e-05	0.000348	CcSEcCtD
Bosutinib—Dermatitis—Estradiol—prostate cancer	3.5e-05	0.000348	CcSEcCtD
Bosutinib—Anaemia—Prednisone—prostate cancer	3.49e-05	0.000347	CcSEcCtD
Bosutinib—Headache—Estradiol—prostate cancer	3.48e-05	0.000346	CcSEcCtD
Bosutinib—Skin disorder—Docetaxel—prostate cancer	3.47e-05	0.000345	CcSEcCtD
Bosutinib—Oedema—Capecitabine—prostate cancer	3.46e-05	0.000344	CcSEcCtD
Bosutinib—Renal failure—Doxorubicin—prostate cancer	3.44e-05	0.000342	CcSEcCtD
Bosutinib—Infection—Capecitabine—prostate cancer	3.44e-05	0.000342	CcSEcCtD
Bosutinib—Urticaria—Etoposide—prostate cancer	3.42e-05	0.00034	CcSEcCtD
Bosutinib—Malaise—Prednisone—prostate cancer	3.41e-05	0.000339	CcSEcCtD
Bosutinib—CHEK2—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	3.4e-05	0.0118	CbGdCrCtD
Bosutinib—Body temperature increased—Etoposide—prostate cancer	3.4e-05	0.000338	CcSEcCtD
Bosutinib—Abdominal pain—Etoposide—prostate cancer	3.4e-05	0.000338	CcSEcCtD
Bosutinib—Nervous system disorder—Capecitabine—prostate cancer	3.4e-05	0.000338	CcSEcCtD
Bosutinib—Hepatitis—Epirubicin—prostate cancer	3.4e-05	0.000338	CcSEcCtD
Bosutinib—Thrombocytopenia—Capecitabine—prostate cancer	3.39e-05	0.000337	CcSEcCtD
Bosutinib—Skin disorder—Capecitabine—prostate cancer	3.36e-05	0.000334	CcSEcCtD
Bosutinib—Urinary tract disorder—Epirubicin—prostate cancer	3.35e-05	0.000333	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—prostate cancer	3.34e-05	0.000333	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—prostate cancer	3.34e-05	0.000332	CcSEcCtD
Bosutinib—Urethral disorder—Epirubicin—prostate cancer	3.33e-05	0.000331	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—prostate cancer	3.31e-05	0.000329	CcSEcCtD
Bosutinib—Nausea—Estradiol—prostate cancer	3.3e-05	0.000328	CcSEcCtD
Bosutinib—Vomiting—Mitoxantrone—prostate cancer	3.29e-05	0.000327	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—prostate cancer	3.27e-05	0.000325	CcSEcCtD
Bosutinib—Rash—Mitoxantrone—prostate cancer	3.26e-05	0.000324	CcSEcCtD
Bosutinib—Dermatitis—Mitoxantrone—prostate cancer	3.26e-05	0.000324	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.26e-05	0.000324	CcSEcCtD
Bosutinib—Headache—Mitoxantrone—prostate cancer	3.24e-05	0.000322	CcSEcCtD
Bosutinib—CHEK2—Fulvestrant—Estradiol—prostate cancer	3.24e-05	0.0112	CbGdCrCtD
Bosutinib—Arthralgia—Prednisone—prostate cancer	3.22e-05	0.00032	CcSEcCtD
Bosutinib—Myalgia—Prednisone—prostate cancer	3.22e-05	0.00032	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—prostate cancer	3.21e-05	0.000319	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.2e-05	0.000318	CcSEcCtD
Bosutinib—Dyspnoea—Docetaxel—prostate cancer	3.19e-05	0.000317	CcSEcCtD
Bosutinib—Discomfort—Prednisone—prostate cancer	3.18e-05	0.000316	CcSEcCtD
Bosutinib—Tinnitus—Epirubicin—prostate cancer	3.17e-05	0.000315	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.15e-05	0.000314	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—prostate cancer	3.15e-05	0.000313	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—prostate cancer	3.14e-05	0.000312	CcSEcCtD
Bosutinib—Decreased appetite—Docetaxel—prostate cancer	3.11e-05	0.000309	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—prostate cancer	3.1e-05	0.000309	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—prostate cancer	3.09e-05	0.000308	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Docetaxel—prostate cancer	3.09e-05	0.000307	CcSEcCtD
Bosutinib—Asthenia—Etoposide—prostate cancer	3.09e-05	0.000307	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—prostate cancer	3.09e-05	0.000307	CcSEcCtD
Bosutinib—Dyspnoea—Capecitabine—prostate cancer	3.09e-05	0.000307	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisone—prostate cancer	3.08e-05	0.000307	CcSEcCtD
Bosutinib—Oedema—Prednisone—prostate cancer	3.08e-05	0.000307	CcSEcCtD
Bosutinib—Fatigue—Docetaxel—prostate cancer	3.08e-05	0.000307	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—prostate cancer	3.08e-05	0.000306	CcSEcCtD
Bosutinib—Nausea—Mitoxantrone—prostate cancer	3.07e-05	0.000306	CcSEcCtD
Bosutinib—ABCB1—epithelium—prostate cancer	3.07e-05	0.000364	CbGeAlD
Bosutinib—Immune system disorder—Epirubicin—prostate cancer	3.07e-05	0.000305	CcSEcCtD
Bosutinib—Infection—Prednisone—prostate cancer	3.06e-05	0.000305	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—prostate cancer	3.06e-05	0.000304	CcSEcCtD
Bosutinib—Pain—Docetaxel—prostate cancer	3.06e-05	0.000304	CcSEcCtD
Bosutinib—Pruritus—Etoposide—prostate cancer	3.04e-05	0.000303	CcSEcCtD
Bosutinib—Nervous system disorder—Prednisone—prostate cancer	3.02e-05	0.000301	CcSEcCtD
Bosutinib—Decreased appetite—Capecitabine—prostate cancer	3.01e-05	0.000299	CcSEcCtD
Bosutinib—Skin disorder—Prednisone—prostate cancer	3e-05	0.000298	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Capecitabine—prostate cancer	2.99e-05	0.000297	CcSEcCtD
Bosutinib—Fatigue—Capecitabine—prostate cancer	2.99e-05	0.000297	CcSEcCtD
Bosutinib—Erythema multiforme—Doxorubicin—prostate cancer	2.97e-05	0.000295	CcSEcCtD
Bosutinib—Pain—Capecitabine—prostate cancer	2.96e-05	0.000294	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—prostate cancer	2.96e-05	0.000294	CcSEcCtD
Bosutinib—Feeling abnormal—Docetaxel—prostate cancer	2.95e-05	0.000293	CcSEcCtD
Bosutinib—Diarrhoea—Etoposide—prostate cancer	2.94e-05	0.000293	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—prostate cancer	2.93e-05	0.000291	CcSEcCtD
Bosutinib—Gastrointestinal pain—Docetaxel—prostate cancer	2.92e-05	0.000291	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—prostate cancer	2.92e-05	0.00029	CcSEcCtD
Bosutinib—PKMYT1—Danazol—Ethinyl Estradiol—prostate cancer	2.89e-05	0.01	CbGdCrCtD
Bosutinib—Dysgeusia—Epirubicin—prostate cancer	2.89e-05	0.000288	CcSEcCtD
Bosutinib—Back pain—Epirubicin—prostate cancer	2.86e-05	0.000284	CcSEcCtD
Bosutinib—Feeling abnormal—Capecitabine—prostate cancer	2.85e-05	0.000284	CcSEcCtD
Bosutinib—CHEK2—Teniposide—Etoposide—prostate cancer	2.85e-05	0.00987	CbGdCrCtD
Bosutinib—CHEK2—Podofilox—Etoposide—prostate cancer	2.85e-05	0.00987	CbGdCrCtD
Bosutinib—ABCB1—renal system—prostate cancer	2.85e-05	0.000337	CbGeAlD
Bosutinib—Dizziness—Etoposide—prostate cancer	2.85e-05	0.000283	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—prostate cancer	2.84e-05	0.000282	CcSEcCtD
Bosutinib—Gastrointestinal pain—Capecitabine—prostate cancer	2.83e-05	0.000282	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—prostate cancer	2.83e-05	0.000282	CcSEcCtD
Bosutinib—Abdominal pain—Docetaxel—prostate cancer	2.83e-05	0.000281	CcSEcCtD
Bosutinib—Body temperature increased—Docetaxel—prostate cancer	2.83e-05	0.000281	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Prednisone—prostate cancer	2.81e-05	0.000279	CcSEcCtD
Bosutinib—ABCB1—urethra—prostate cancer	2.8e-05	0.000332	CbGeAlD
Bosutinib—CSNK1E—Danazol—Ethinyl Estradiol—prostate cancer	2.76e-05	0.00956	CbGdCrCtD
Bosutinib—Urticaria—Capecitabine—prostate cancer	2.75e-05	0.000274	CcSEcCtD
Bosutinib—Ill-defined disorder—Epirubicin—prostate cancer	2.74e-05	0.000273	CcSEcCtD
Bosutinib—Body temperature increased—Capecitabine—prostate cancer	2.74e-05	0.000272	CcSEcCtD
Bosutinib—Abdominal pain—Capecitabine—prostate cancer	2.74e-05	0.000272	CcSEcCtD
Bosutinib—Vomiting—Etoposide—prostate cancer	2.74e-05	0.000272	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—prostate cancer	2.73e-05	0.000272	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—prostate cancer	2.73e-05	0.000272	CcSEcCtD
Bosutinib—Rash—Etoposide—prostate cancer	2.71e-05	0.00027	CcSEcCtD
Bosutinib—Dermatitis—Etoposide—prostate cancer	2.71e-05	0.00027	CcSEcCtD
Bosutinib—Headache—Etoposide—prostate cancer	2.7e-05	0.000268	CcSEcCtD
Bosutinib—ABL1—Levorphanol—Estrone—prostate cancer	2.69e-05	0.00933	CbGdCrCtD
Bosutinib—Decreased appetite—Prednisone—prostate cancer	2.68e-05	0.000267	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—prostate cancer	2.68e-05	0.000266	CcSEcCtD
Bosutinib—Malaise—Epirubicin—prostate cancer	2.67e-05	0.000265	CcSEcCtD
Bosutinib—Fatigue—Prednisone—prostate cancer	2.66e-05	0.000264	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—prostate cancer	2.65e-05	0.000263	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—prostate cancer	2.65e-05	0.000263	CcSEcCtD
Bosutinib—Cough—Epirubicin—prostate cancer	2.58e-05	0.000256	CcSEcCtD
Bosutinib—Asthenia—Docetaxel—prostate cancer	2.57e-05	0.000255	CcSEcCtD
Bosutinib—Nausea—Etoposide—prostate cancer	2.56e-05	0.000254	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisone—prostate cancer	2.54e-05	0.000253	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—prostate cancer	2.54e-05	0.000252	CcSEcCtD
Bosutinib—Pruritus—Docetaxel—prostate cancer	2.53e-05	0.000252	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—prostate cancer	2.53e-05	0.000251	CcSEcCtD
Bosutinib—Gastrointestinal pain—Prednisone—prostate cancer	2.52e-05	0.000251	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—prostate cancer	2.52e-05	0.00025	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—prostate cancer	2.52e-05	0.00025	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—prostate cancer	2.52e-05	0.00025	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.5e-05	0.000248	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—prostate cancer	2.49e-05	0.000247	CcSEcCtD
Bosutinib—Asthenia—Capecitabine—prostate cancer	2.48e-05	0.000247	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—prostate cancer	2.47e-05	0.000245	CcSEcCtD
Bosutinib—Urticaria—Prednisone—prostate cancer	2.45e-05	0.000244	CcSEcCtD
Bosutinib—Pruritus—Capecitabine—prostate cancer	2.45e-05	0.000244	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—prostate cancer	2.45e-05	0.000243	CcSEcCtD
Bosutinib—Diarrhoea—Docetaxel—prostate cancer	2.45e-05	0.000243	CcSEcCtD
Bosutinib—Abdominal pain—Prednisone—prostate cancer	2.44e-05	0.000242	CcSEcCtD
Bosutinib—Body temperature increased—Prednisone—prostate cancer	2.44e-05	0.000242	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—prostate cancer	2.41e-05	0.00024	CcSEcCtD
Bosutinib—Oedema—Epirubicin—prostate cancer	2.41e-05	0.00024	CcSEcCtD
Bosutinib—Infection—Epirubicin—prostate cancer	2.4e-05	0.000238	CcSEcCtD
Bosutinib—Cough—Doxorubicin—prostate cancer	2.39e-05	0.000237	CcSEcCtD
Bosutinib—Diarrhoea—Capecitabine—prostate cancer	2.37e-05	0.000236	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—prostate cancer	2.37e-05	0.000235	CcSEcCtD
Bosutinib—Dizziness—Docetaxel—prostate cancer	2.37e-05	0.000235	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—prostate cancer	2.36e-05	0.000235	CcSEcCtD
Bosutinib—Skin disorder—Epirubicin—prostate cancer	2.34e-05	0.000233	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—prostate cancer	2.33e-05	0.000232	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—prostate cancer	2.33e-05	0.000232	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—prostate cancer	2.33e-05	0.000232	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.31e-05	0.00023	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—prostate cancer	2.3e-05	0.000229	CcSEcCtD
Bosutinib—Dizziness—Capecitabine—prostate cancer	2.29e-05	0.000228	CcSEcCtD
Bosutinib—Vomiting—Docetaxel—prostate cancer	2.27e-05	0.000226	CcSEcCtD
Bosutinib—Rash—Docetaxel—prostate cancer	2.25e-05	0.000224	CcSEcCtD
Bosutinib—Dermatitis—Docetaxel—prostate cancer	2.25e-05	0.000224	CcSEcCtD
Bosutinib—Headache—Docetaxel—prostate cancer	2.24e-05	0.000223	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—prostate cancer	2.23e-05	0.000222	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—prostate cancer	2.23e-05	0.000222	CcSEcCtD
Bosutinib—Infection—Doxorubicin—prostate cancer	2.22e-05	0.00022	CcSEcCtD
Bosutinib—Asthenia—Prednisone—prostate cancer	2.21e-05	0.00022	CcSEcCtD
Bosutinib—Vomiting—Capecitabine—prostate cancer	2.2e-05	0.000219	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.2e-05	0.000219	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—prostate cancer	2.19e-05	0.000218	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—prostate cancer	2.19e-05	0.000217	CcSEcCtD
Bosutinib—Rash—Capecitabine—prostate cancer	2.18e-05	0.000217	CcSEcCtD
Bosutinib—Pruritus—Prednisone—prostate cancer	2.18e-05	0.000217	CcSEcCtD
Bosutinib—Dermatitis—Capecitabine—prostate cancer	2.18e-05	0.000217	CcSEcCtD
Bosutinib—Headache—Capecitabine—prostate cancer	2.17e-05	0.000216	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—prostate cancer	2.17e-05	0.000216	CcSEcCtD
Bosutinib—ABCB1—bone marrow—prostate cancer	2.15e-05	0.000255	CbGeAlD
Bosutinib—Dyspnoea—Epirubicin—prostate cancer	2.15e-05	0.000214	CcSEcCtD
Bosutinib—Nausea—Docetaxel—prostate cancer	2.12e-05	0.000211	CcSEcCtD
Bosutinib—Diarrhoea—Prednisone—prostate cancer	2.11e-05	0.00021	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—prostate cancer	2.1e-05	0.000209	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—prostate cancer	2.08e-05	0.000207	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—prostate cancer	2.08e-05	0.000207	CcSEcCtD
Bosutinib—Pain—Epirubicin—prostate cancer	2.06e-05	0.000205	CcSEcCtD
Bosutinib—Nausea—Capecitabine—prostate cancer	2.06e-05	0.000205	CcSEcCtD
Bosutinib—ABL1—Levorphanol—Estradiol—prostate cancer	2.04e-05	0.00707	CbGdCrCtD
Bosutinib—Dizziness—Prednisone—prostate cancer	2.04e-05	0.000203	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.03e-05	0.000202	CcSEcCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—prostate cancer	2.03e-05	0.00704	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—prostate cancer	2.03e-05	0.00704	CbGdCrCtD
Bosutinib—Dyspnoea—Doxorubicin—prostate cancer	1.99e-05	0.000198	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—prostate cancer	1.99e-05	0.000198	CcSEcCtD
Bosutinib—Gastrointestinal pain—Epirubicin—prostate cancer	1.97e-05	0.000196	CcSEcCtD
Bosutinib—Vomiting—Prednisone—prostate cancer	1.96e-05	0.000195	CcSEcCtD
Bosutinib—Rash—Prednisone—prostate cancer	1.94e-05	0.000193	CcSEcCtD
Bosutinib—Dermatitis—Prednisone—prostate cancer	1.94e-05	0.000193	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—prostate cancer	1.94e-05	0.000193	CcSEcCtD
Bosutinib—Headache—Prednisone—prostate cancer	1.93e-05	0.000192	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.93e-05	0.000192	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—prostate cancer	1.92e-05	0.000191	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—prostate cancer	1.92e-05	0.000191	CcSEcCtD
Bosutinib—Pain—Doxorubicin—prostate cancer	1.91e-05	0.00019	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—prostate cancer	1.91e-05	0.00019	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—prostate cancer	1.91e-05	0.00019	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—prostate cancer	1.88e-05	0.00651	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—prostate cancer	1.88e-05	0.00651	CbGdCrCtD
Bosutinib—ABCB1—testis—prostate cancer	1.84e-05	0.000218	CbGeAlD
Bosutinib—Feeling abnormal—Doxorubicin—prostate cancer	1.84e-05	0.000183	CcSEcCtD
Bosutinib—Nausea—Prednisone—prostate cancer	1.83e-05	0.000182	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—prostate cancer	1.83e-05	0.000181	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Prednisone—prostate cancer	1.79e-05	0.00621	CbGdCrCtD
Bosutinib—Urticaria—Doxorubicin—prostate cancer	1.77e-05	0.000176	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—prostate cancer	1.76e-05	0.000175	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—prostate cancer	1.76e-05	0.000175	CcSEcCtD
Bosutinib—Asthenia—Epirubicin—prostate cancer	1.73e-05	0.000172	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—prostate cancer	1.71e-05	0.00017	CcSEcCtD
Bosutinib—Diarrhoea—Epirubicin—prostate cancer	1.65e-05	0.000164	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—prostate cancer	1.6e-05	0.000159	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—prostate cancer	1.6e-05	0.000159	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—prostate cancer	1.58e-05	0.000157	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—prostate cancer	1.53e-05	0.000153	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—prostate cancer	1.53e-05	0.000152	CcSEcCtD
Bosutinib—Rash—Epirubicin—prostate cancer	1.52e-05	0.000151	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—prostate cancer	1.52e-05	0.000151	CcSEcCtD
Bosutinib—Headache—Epirubicin—prostate cancer	1.51e-05	0.00015	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—prostate cancer	1.49e-05	0.00515	CbGdCrCtD
Bosutinib—Dizziness—Doxorubicin—prostate cancer	1.48e-05	0.000147	CcSEcCtD
Bosutinib—Nausea—Epirubicin—prostate cancer	1.43e-05	0.000142	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—prostate cancer	1.42e-05	0.000141	CcSEcCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—prostate cancer	1.42e-05	0.00491	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—prostate cancer	1.42e-05	0.00491	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—prostate cancer	1.42e-05	0.00491	CbGdCrCtD
Bosutinib—CHEK2—Danazol—Ethinyl Estradiol—prostate cancer	1.41e-05	0.0049	CbGdCrCtD
Bosutinib—Rash—Doxorubicin—prostate cancer	1.41e-05	0.00014	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—prostate cancer	1.41e-05	0.00014	CcSEcCtD
Bosutinib—Headache—Doxorubicin—prostate cancer	1.4e-05	0.000139	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—prostate cancer	1.38e-05	0.00477	CbGdCrCtD
Bosutinib—ABCB1—lymph node—prostate cancer	1.33e-05	0.000158	CbGeAlD
Bosutinib—Nausea—Doxorubicin—prostate cancer	1.33e-05	0.000132	CcSEcCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—prostate cancer	1.31e-05	0.00455	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—prostate cancer	1.31e-05	0.00455	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—prostate cancer	1.31e-05	0.00455	CbGdCrCtD
Bosutinib—CHEK2—Norethindrone—Ethinyl Estradiol—prostate cancer	1.27e-05	0.00441	CbGdCrCtD
Bosutinib—PKMYT1—Danazol—Prednisone—prostate cancer	1.02e-05	0.00352	CbGdCrCtD
Bosutinib—CHEK2—Levonorgestrel—Ethinyl Estradiol—prostate cancer	1.01e-05	0.00351	CbGdCrCtD
Bosutinib—CSNK1E—Danazol—Prednisone—prostate cancer	9.7e-06	0.00336	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisone—prostate cancer	6.19e-06	0.00214	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Prednisone—prostate cancer	6.19e-06	0.00214	CbGdCrCtD
Bosutinib—CHEK2—Danazol—Prednisone—prostate cancer	4.97e-06	0.00172	CbGdCrCtD
Bosutinib—MAP2K2—Signaling Pathways—SRC—prostate cancer	1.7e-07	1.17e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—prostate cancer	1.7e-07	1.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAP2K1—prostate cancer	1.7e-07	1.17e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—prostate cancer	1.7e-07	1.17e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PRKACB—prostate cancer	1.7e-07	1.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CD—prostate cancer	1.69e-07	1.16e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—prostate cancer	1.69e-07	1.16e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—prostate cancer	1.69e-07	1.16e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—prostate cancer	1.68e-07	1.16e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.68e-07	1.16e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—prostate cancer	1.68e-07	1.16e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—prostate cancer	1.68e-07	1.15e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EP300—prostate cancer	1.67e-07	1.15e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SERPINE1—prostate cancer	1.67e-07	1.15e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—prostate cancer	1.67e-07	1.15e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—prostate cancer	1.67e-07	1.15e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CB—prostate cancer	1.67e-07	1.15e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—prostate cancer	1.66e-07	1.15e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SRC—prostate cancer	1.66e-07	1.15e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—prostate cancer	1.66e-07	1.14e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—prostate cancer	1.66e-07	1.14e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—prostate cancer	1.66e-07	1.14e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—prostate cancer	1.66e-07	1.14e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EP300—prostate cancer	1.65e-07	1.14e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—prostate cancer	1.64e-07	1.13e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EP300—prostate cancer	1.64e-07	1.13e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—prostate cancer	1.64e-07	1.13e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—prostate cancer	1.64e-07	1.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—prostate cancer	1.64e-07	1.13e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—prostate cancer	1.63e-07	1.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—prostate cancer	1.63e-07	1.12e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SRC—prostate cancer	1.63e-07	1.12e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—prostate cancer	1.63e-07	1.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1B—prostate cancer	1.62e-07	1.12e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—prostate cancer	1.62e-07	1.12e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—prostate cancer	1.62e-07	1.12e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGF2—prostate cancer	1.62e-07	1.12e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—prostate cancer	1.61e-07	1.11e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—prostate cancer	1.61e-07	1.11e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—prostate cancer	1.6e-07	1.1e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—prostate cancer	1.6e-07	1.1e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—prostate cancer	1.6e-07	1.1e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SRC—prostate cancer	1.6e-07	1.1e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—prostate cancer	1.6e-07	1.1e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—prostate cancer	1.6e-07	1.1e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—prostate cancer	1.6e-07	1.1e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NCOA2—prostate cancer	1.6e-07	1.1e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—prostate cancer	1.6e-07	1.1e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—prostate cancer	1.6e-07	1.1e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SRC—prostate cancer	1.59e-07	1.1e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARA—prostate cancer	1.59e-07	1.09e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—prostate cancer	1.59e-07	1.09e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—prostate cancer	1.59e-07	1.09e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—prostate cancer	1.59e-07	1.09e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—prostate cancer	1.58e-07	1.09e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—prostate cancer	1.58e-07	1.09e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—prostate cancer	1.58e-07	1.08e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—prostate cancer	1.57e-07	1.08e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—prostate cancer	1.57e-07	1.08e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—prostate cancer	1.57e-07	1.08e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1B—prostate cancer	1.56e-07	1.08e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—prostate cancer	1.56e-07	1.08e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—prostate cancer	1.56e-07	1.07e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—prostate cancer	1.55e-07	1.07e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JAK2—prostate cancer	1.55e-07	1.07e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—prostate cancer	1.55e-07	1.07e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—prostate cancer	1.55e-07	1.06e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—prostate cancer	1.55e-07	1.06e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—prostate cancer	1.54e-07	1.06e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—prostate cancer	1.54e-07	1.06e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—prostate cancer	1.54e-07	1.06e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—prostate cancer	1.53e-07	1.06e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—prostate cancer	1.53e-07	1.06e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—prostate cancer	1.53e-07	1.06e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—prostate cancer	1.53e-07	1.05e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—prostate cancer	1.53e-07	1.05e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—prostate cancer	1.53e-07	1.05e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.53e-07	1.05e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—prostate cancer	1.52e-07	1.05e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—prostate cancer	1.52e-07	1.05e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MDM2—prostate cancer	1.52e-07	1.04e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—prostate cancer	1.51e-07	1.04e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—prostate cancer	1.51e-07	1.04e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—prostate cancer	1.51e-07	1.04e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—prostate cancer	1.51e-07	1.04e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—prostate cancer	1.5e-07	1.04e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—prostate cancer	1.5e-07	1.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1A—prostate cancer	1.5e-07	1.03e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CAV1—prostate cancer	1.49e-07	1.03e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—prostate cancer	1.49e-07	1.03e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—prostate cancer	1.49e-07	1.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—prostate cancer	1.49e-07	1.03e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—prostate cancer	1.49e-07	1.03e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—prostate cancer	1.49e-07	1.03e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.49e-07	1.03e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—prostate cancer	1.49e-07	1.03e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—prostate cancer	1.49e-07	1.02e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—prostate cancer	1.48e-07	1.02e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—prostate cancer	1.48e-07	1.02e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—prostate cancer	1.48e-07	1.02e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—prostate cancer	1.48e-07	1.02e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CB—prostate cancer	1.47e-07	1.02e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NQO1—prostate cancer	1.47e-07	1.01e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—prostate cancer	1.47e-07	1.01e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—prostate cancer	1.46e-07	1e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—prostate cancer	1.46e-07	1e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—prostate cancer	1.46e-07	1e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—prostate cancer	1.46e-07	1e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TH—prostate cancer	1.45e-07	1e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—prostate cancer	1.45e-07	9.98e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—prostate cancer	1.45e-07	9.97e-07	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—prostate cancer	1.44e-07	9.94e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1A—prostate cancer	1.44e-07	9.93e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—prostate cancer	1.44e-07	9.91e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—prostate cancer	1.44e-07	9.89e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—prostate cancer	1.44e-07	9.88e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—prostate cancer	1.43e-07	9.87e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—prostate cancer	1.43e-07	9.84e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—prostate cancer	1.43e-07	9.83e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—prostate cancer	1.43e-07	9.81e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EP300—prostate cancer	1.42e-07	9.81e-07	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—prostate cancer	1.42e-07	9.8e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—prostate cancer	1.42e-07	9.76e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—prostate cancer	1.42e-07	9.74e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.41e-07	9.73e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—prostate cancer	1.41e-07	9.72e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—prostate cancer	1.41e-07	9.68e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—prostate cancer	1.4e-07	9.62e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—prostate cancer	1.4e-07	9.62e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—prostate cancer	1.4e-07	9.61e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—prostate cancer	1.39e-07	9.58e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—prostate cancer	1.39e-07	9.57e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SRC—prostate cancer	1.39e-07	9.54e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1B—prostate cancer	1.38e-07	9.53e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—prostate cancer	1.38e-07	9.48e-07	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—prostate cancer	1.38e-07	9.48e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EP300—prostate cancer	1.37e-07	9.45e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GGT1—prostate cancer	1.37e-07	9.42e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—prostate cancer	1.36e-07	9.38e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—prostate cancer	1.36e-07	9.34e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—prostate cancer	1.36e-07	9.34e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—prostate cancer	1.35e-07	9.32e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—prostate cancer	1.35e-07	9.29e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—prostate cancer	1.35e-07	9.28e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NCOA1—prostate cancer	1.35e-07	9.28e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—prostate cancer	1.34e-07	9.2e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SRC—prostate cancer	1.33e-07	9.19e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—prostate cancer	1.33e-07	9.17e-07	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—prostate cancer	1.33e-07	9.17e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.33e-07	9.15e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—prostate cancer	1.33e-07	9.14e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—prostate cancer	1.32e-07	9.09e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—prostate cancer	1.32e-07	9.09e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—prostate cancer	1.31e-07	9.05e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—prostate cancer	1.31e-07	9e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—prostate cancer	1.3e-07	8.95e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—prostate cancer	1.3e-07	8.93e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—INS—prostate cancer	1.29e-07	8.87e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—prostate cancer	1.29e-07	8.86e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—prostate cancer	1.29e-07	8.86e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—prostate cancer	1.28e-07	8.84e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—prostate cancer	1.28e-07	8.84e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—prostate cancer	1.28e-07	8.83e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—RXRA—prostate cancer	1.28e-07	8.83e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—prostate cancer	1.28e-07	8.82e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1A—prostate cancer	1.28e-07	8.79e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—prostate cancer	1.27e-07	8.77e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—prostate cancer	1.27e-07	8.71e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CREBBP—prostate cancer	1.26e-07	8.69e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—prostate cancer	1.25e-07	8.64e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—prostate cancer	1.24e-07	8.55e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—prostate cancer	1.24e-07	8.53e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—prostate cancer	1.24e-07	8.53e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—COMT—prostate cancer	1.24e-07	8.5e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—prostate cancer	1.23e-07	8.48e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—prostate cancer	1.23e-07	8.46e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—prostate cancer	1.23e-07	8.46e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—prostate cancer	1.22e-07	8.43e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—prostate cancer	1.22e-07	8.4e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EP300—prostate cancer	1.22e-07	8.37e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—prostate cancer	1.21e-07	8.35e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—prostate cancer	1.21e-07	8.35e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ITPR1—prostate cancer	1.21e-07	8.33e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—prostate cancer	1.2e-07	8.25e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CD—prostate cancer	1.2e-07	8.24e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—prostate cancer	1.2e-07	8.24e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—prostate cancer	1.19e-07	8.22e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—prostate cancer	1.18e-07	8.16e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—prostate cancer	1.18e-07	8.12e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—prostate cancer	1.17e-07	8.08e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—prostate cancer	1.17e-07	8.06e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—prostate cancer	1.15e-07	7.92e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—prostate cancer	1.15e-07	7.91e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—prostate cancer	1.15e-07	7.9e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMS—prostate cancer	1.14e-07	7.87e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—prostate cancer	1.14e-07	7.85e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—prostate cancer	1.14e-07	7.83e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—prostate cancer	1.14e-07	7.82e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—prostate cancer	1.13e-07	7.78e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—prostate cancer	1.13e-07	7.78e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—prostate cancer	1.12e-07	7.71e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LPL—prostate cancer	1.11e-07	7.64e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—prostate cancer	1.11e-07	7.61e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—prostate cancer	1.1e-07	7.55e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—prostate cancer	1.08e-07	7.44e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—prostate cancer	1.07e-07	7.4e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.07e-07	7.37e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ERCC2—prostate cancer	1.06e-07	7.31e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—prostate cancer	1.06e-07	7.29e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—prostate cancer	1.06e-07	7.29e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—prostate cancer	1.06e-07	7.27e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—prostate cancer	1.05e-07	7.25e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—prostate cancer	1.05e-07	7.22e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CB—prostate cancer	1.04e-07	7.18e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—prostate cancer	1.04e-07	7.13e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—prostate cancer	1.03e-07	7.12e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—prostate cancer	1.03e-07	7.12e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—prostate cancer	1.02e-07	7.02e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—prostate cancer	1.02e-07	6.99e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—prostate cancer	1.01e-07	6.97e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—prostate cancer	9.98e-08	6.87e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—prostate cancer	9.96e-08	6.86e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—prostate cancer	9.91e-08	6.82e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—prostate cancer	9.82e-08	6.76e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARA—prostate cancer	9.8e-08	6.74e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—prostate cancer	9.78e-08	6.74e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—prostate cancer	9.33e-08	6.42e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAV1—prostate cancer	9.21e-08	6.34e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—prostate cancer	9.02e-08	6.21e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—prostate cancer	8.99e-08	6.19e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—prostate cancer	8.99e-08	6.19e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—prostate cancer	8.7e-08	5.99e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—prostate cancer	8.61e-08	5.93e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—EP300—prostate cancer	8.6e-08	5.92e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—prostate cancer	8.39e-08	5.78e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—prostate cancer	8.29e-08	5.71e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—prostate cancer	7.96e-08	5.48e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—INS—prostate cancer	7.94e-08	5.47e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CREBBP—prostate cancer	7.78e-08	5.36e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CD—prostate cancer	7.37e-08	5.08e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—prostate cancer	7.34e-08	5.06e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—prostate cancer	6.96e-08	4.79e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CB—prostate cancer	6.43e-08	4.43e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—prostate cancer	6.37e-08	4.39e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—prostate cancer	6.36e-08	4.38e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—prostate cancer	5.55e-08	3.82e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—EP300—prostate cancer	5.3e-08	3.65e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—prostate cancer	5.2e-08	3.58e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.92e-08	2.7e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—prostate cancer	3.2e-08	2.2e-07	CbGpPWpGaD
